Alnylam Pharmaceuticals

biopharmaceutical company

ALNY Nasdaq ISIN US02043Q1076 SEC CIK 1178670 LEI 529900S3ZI14OWRJII50
Follow Alnylam Pharmaceuticals Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $1.5B +16.7% vs same quarter last year
Net income $2.2B +640.5% vs same quarter last year
EPS, diluted $15.72 +634.6% vs same quarter last year
Operating cash flow $341M +14.9% vs same quarter last year
Revenue by quarter
$593.2M
$594.2M
$773.7M
$1.2B
$1.1B
$1.3B
$1.5B
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income15 fiscal years
  • Revenue
  • Net income
−$2B$0$2B$4BFY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25$3.7B$313.7M
FY24$2.2B−$278.2M
FY23$1.8B−$440.2M
FY22$1B−$1.1B
FY21$844.3M−$852.8M
FY20$492.9M−$858.3M
FY19$219.8M−$886.1M
FY18$74.9M−$761.5M
FY17$89.9M−$490.9M
FY16$47.2M−$410.1M
FY15-−$290.1M
FY14-−$360.4M
FY13-−$89.2M
FY12-−$106M
FY11-−$57.6M
MarginsShare of revenue
  • Gross margin
  • Operating margin
  • Net margin
−1500%−1000%−500%0%500%FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearGross marginOperating marginNet margin
FY2581.8%13.5%8.4%
FY2486.4%−7.9%−12.4%
FY2385.3%−15.4%−24.1%
FY2286.5%−75.7%−109%
FY2186.4%−83.9%−101%
FY2084.9%−168.1%−174.1%
FY1988.6%−427.5%−403.2%
FY1897.6%−1087.6%−1016.6%
FY17100%−556.2%−545.9%
FY16-−900.3%−869.6%
FY15---
FY14---
FY13---
FY12---
FY11---
Free cash flowOperating cash flow minus capital expenditure
−$1B−$500M$0$500MFY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25$465.4M
FY24−$42.6M
FY23$41.9M
FY22−$613.3M
FY21−$718.1M
FY20−$685.3M
FY19−$418.6M
FY18−$689.5M
FY17−$487M
FY16−$372.3M
FY15−$202.1M
FY14−$174.6M
FY13−$72.7M
FY12−$124M
FY11−$88.4M
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Alnylam Pharmaceuticals
  • Healthcare median
−1500%−1000%−500%0%500%FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearAlnylam PharmaceuticalsHealthcare median
FY258.4%−30.6%
FY24−12.4%−47%
FY23−24.1%−58%
FY22−109%−80.4%
FY21−101%−71.9%
FY20−174.1%−62.2%
FY19−403.2%−46.3%
FY18−1016.6%−49.6%
FY17−545.9%−45.9%
FY16−869.6%−36%
FY15-−38.4%
FY14-−35.5%
FY13-−37.1%
FY12-−29.1%
FY11-−27.9%